Search Results - "D"alise, C"

Refine Results
  1. 1

    New β-Lactam-β-Lactamase Inhibitor Combinations by Yahav, Dafna, Giske, Christian G, Grāmatniece, Alise, Abodakpi, Henrietta, Tam, Vincent H, Leibovici, Leonard

    Published in Clinical microbiology reviews (16-12-2020)
    “…The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam-β-lactamase inhibitor combinations…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Financial management and perioperative leadership in the ambulatory setting journal title: Best practice in clinical research by Abdullahi, Adamu, Roberts, Timothy Dean, Daniel, Charles P., Aucoin, Alise J., Ingram, Ellen E., Corley, Sarah C., Cornett, Elyse M., Kaye, Alan D.

    “…A large portion of US healthcare is ambulatory. Strong leadership is vital for the safety and efficiency of perioperative patients in this setting. Good…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis by Bombardier, Claire, Laine, Loren, Reicin, Alise, Shapiro, Deborah, Burgos-Vargas, Ruben, Davis, Barry, Day, Richard, Ferraz, Marcos Bosi, Hawkey, Christopher J, Hochberg, Marc C, Kvien, Tore K, Schnitzer, Thomas J

    Published in The New England journal of medicine (23-11-2000)
    “…Nonsteroidal antiinflammatory drugs (NSAIDs) are among the most commonly used medications in the world. 1 A major factor limiting their use is gastrointestinal…”
    Get full text
    Journal Article
  12. 12

    On Extending the Wave Variable Method to Multiple-DOF Teleoperation Systems by Alise, Marc, Roberts, Rodney G., Repperger, Daniel W., Moore, Carl A., Tosunoglu, Sabri

    Published in IEEE/ASME transactions on mechatronics (01-02-2009)
    “…It is well known that providing a human operator with contact force information can significantly improve task performance in a teleoperation system…”
    Get full text
    Journal Article
  13. 13

    Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis by Laine, Loren, Bombardier, Claire, Hawkey, Christopher J., Davis, Barry, Shapiro, Deborah, Brett, Christopher, Reicin, Alise

    Published in Gastroenterology (New York, N.Y. 1943) (01-10-2002)
    “…Background & Aims: Epidemiologic data indicate that the risk of nonsteroidal anti-inflammatory drug (NSAID)–related gastrointestinal (GI) clinical events…”
    Get full text
    Journal Article
  14. 14

    Prevention of cyclophosphamide‐induced alopecia by selegiline in a murine model by Berry, Mark D., Gaiser, Alise C., Chapman, Stacy I., Jackson, Patrick

    Published in The FASEB journal (01-04-2013)
    “…Abstract only One of the most common and psychologically traumatic side effects of cancer therapy is the induction of apoptosis in hair follicle cells,…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis by Ramey, Dena R., Watson, Douglas J., Yu, Chang, Bolognese, James A., Curtis, Sean P., Reicin, Alise S.

    Published in Current medical research and opinion (01-05-2005)
    “…Objective: In spite of numerous studies demonstrating the serious gastrointestinal (GI) toxicity associated with non-selective non-steroidal anti-inflammatory…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial by Peters, Katherine B., Vredenburgh, James J., Desjardins, Annick, Friedman, Henry S., Herndon, James Emmett, Coan, April D., McSherry, Frances, Lipp, Eric S, Brickhouse, Alise, Massey, Woody C, Reardon, David A.

    Published in Journal of clinical oncology (20-05-2012)
    “…Abstract only 2027 Background: Prognosis for recurrent glioblastoma (GBM) remains poor with median survival between 3 to 6 months. Use of anti-vascular…”
    Get full text
    Journal Article